Glycotope raises €55m for cancer drugs improved by human glycosylation
This article was originally published in Scrip
German biotech firm Glycotope, which uses its GlycoExpress platform to improve drugs and drug candidates through "human" glycosylation, has raised €55m for the development of its two lead cancer drug candidates, PankoMab-GEX and CetuGEX. Both are in Phase IIb trials slated to complete by the end of 2016. The company's investors, which have now provided total financing in excess of €130m, are Munich-based Jossa Arznei (part of the Strüngmann group) and ELSA (Eckert Life Science Accelerator) in Berlin.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.